Octagon Capital Advisors LP Vera Therapeutics, Inc. Transaction History

Octagon Capital Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$6.11 - $17.83 $4.43 Million - $12.9 Million	-725,000 Reduced 91.19%	70,000 $1.12 Million
Q1 2023 May 15, 2023	BUY	$5.41 - $18.3 $702,456 - $2.38 Million	129,844 Added 19.52%	795,000 $6.17 Million
Q4 2022 Feb 14, 2023	BUY	$15.74 - $22.19 $1.42 Million - $2 Million	90,156 Added 15.68%	665,156 $12.9 Million
Q1 2022 May 16, 2022	SELL	$17.8 - $28.06 $1.71 Million - $2.69 Million	-95,940 Reduced 14.3%	575,000 $13.5 Million
Q4 2021 Feb 14, 2022	SELL	$15.01 - $35.8 $378,041 - $901,658	-25,186 Reduced 3.62%	670,940 $17.9 Million
Q3 2021 Nov 15, 2021	SELL	$13.71 - $30.6 $5.99 Million - $13.4 Million	-436,545 Reduced 38.54%	696,126 $12.1 Million
Q2 2021 Aug 16, 2021	BUY	$11.5 - $19.97 $13 Million - $22.6 Million	1,132,671 New	1,132,671 $15 Million

183

55.6M

134K

156K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.01B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.